Boon Leong Quah1, Andrew Edwards-Bailey1, Kanna Gnanalingham1, Omar Pathmanaban1,2, Hariclea Vasilopoulos1, Federico Roncaroli2,3, Tara Kearney4, James Balogun1,5, Konstantina Karabatsou6,7. 1. Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. 2. Geoffrey Jefferson Brain Research Centre, Division of Neuroscience & Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. 3. Neuropathology Unit, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. 4. Department of Endocrinology, Salford Royal Hospital NHS Foundation Trust, Manchester, UK. 5. Division of Neurosurgery, Department of Surgery, College of Medicine, University of Ibadan, Ibadan, Nigeria. 6. Department of Neurosurgery, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. tina.karabatsou@srft.nhs.uk. 7. Geoffrey Jefferson Brain Research Centre, Division of Neuroscience & Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. tina.karabatsou@srft.nhs.uk.
Abstract
PURPOSE: To assess and compare outcome of surgical management of non-functioning pituitary adenohypophyseal tumours in patients under 65-years, and 65-years and older at tertiary neurosurgical referral centre. METHODS: Data was retrospectively analysed from pituitary database. Forty-four patients aged 65 or older (Group 1) and 93 patients under 65 (Group 2) underwent endoscopic trans-sphenoidal surgery (ETSS) between January 2017 and July 2019. The surgical, endocrinological, ophthalmological and radiological outcomes were compared. RESULTS: 6.8% of Group 1 patients had peri-operative surgical complications compared to 12.9% in Group 2 (p = 0.29). Improved visual fields and acuity were seen in 65.2% and 82.8% of Group 1 and Group 2 respectively (p = 0.124), although there were pre-existing ocular problems in 15.9% of Group 1. New hormone deficiencies were observed in 31.8% of Group 1 patients, and 24.7% of Group 2 (p = 0.555). Tumour regrowth/recurrence was seen in 2.3% of Group 1 (p = 0.553). The rate of repeat surgery was 6.8% in the Group 1 and 12.9% in Group 2 (p = 0.28). There was no significant relationship between extent of resection, complications or hormonal deficiency. The mean duration of follow-up was 10.5 ± 13.0 months for Group 1 patients and 13.0 ± 16.0 months for Group 2 patients (p = 0.526). CONCLUSIONS: ETSS for non-functioning pituitary adenohypophyseal tumours is safe and well tolerated in the patients aged 65 and older. Advanced age by itself should not be a contra-indication for ETSS. It is however highly recommended that the care of such patients to be offered at a high volume, dedicated pituitary surgical units.
PURPOSE: To assess and compare outcome of surgical management of non-functioning pituitary adenohypophyseal tumours in patients under 65-years, and 65-years and older at tertiary neurosurgical referral centre. METHODS: Data was retrospectively analysed from pituitary database. Forty-four patients aged 65 or older (Group 1) and 93 patients under 65 (Group 2) underwent endoscopic trans-sphenoidal surgery (ETSS) between January 2017 and July 2019. The surgical, endocrinological, ophthalmological and radiological outcomes were compared. RESULTS: 6.8% of Group 1 patients had peri-operative surgical complications compared to 12.9% in Group 2 (p = 0.29). Improved visual fields and acuity were seen in 65.2% and 82.8% of Group 1 and Group 2 respectively (p = 0.124), although there were pre-existing ocular problems in 15.9% of Group 1. New hormone deficiencies were observed in 31.8% of Group 1 patients, and 24.7% of Group 2 (p = 0.555). Tumour regrowth/recurrence was seen in 2.3% of Group 1 (p = 0.553). The rate of repeat surgery was 6.8% in the Group 1 and 12.9% in Group 2 (p = 0.28). There was no significant relationship between extent of resection, complications or hormonal deficiency. The mean duration of follow-up was 10.5 ± 13.0 months for Group 1 patients and 13.0 ± 16.0 months for Group 2 patients (p = 0.526). CONCLUSIONS: ETSS for non-functioning pituitary adenohypophyseal tumours is safe and well tolerated in the patients aged 65 and older. Advanced age by itself should not be a contra-indication for ETSS. It is however highly recommended that the care of such patients to be offered at a high volume, dedicated pituitary surgical units.
Authors: Jackson A Gondim; João Paulo Almeida; Lucas Alverne F de Albuquerque; Erika Gomes; Michele Schops; Jose Italo Mota Journal: J Neurosurg Date: 2015-04-03 Impact factor: 5.115
Authors: Bradley D McDowell; Robert B Wallace; Ryan M Carnahan; Elizabeth A Chrischilles; Charles F Lynch; Janet A Schlechte Journal: Pituitary Date: 2011-03 Impact factor: 4.107
Authors: Nicolai Maldaner; Johannes Sarnthein; Oliver Bozinov; Luca Regli; Marian Christoph Neidert Journal: World Neurosurg Date: 2017-11-04 Impact factor: 2.104
Authors: Mohammed A Azab; Molly O'Hagan; Hussam Abou-Al-Shaar; Michael Karsy; Jian Guan; William T Couldwell Journal: World Neurosurg Date: 2018-11-14 Impact factor: 2.104
Authors: Stephanie H Chen; Annelise Sprau; Leon Chieng; Simon Buttrick; Elie S Alam; Sheikh C Ali; Karthik Madhavan; Zoukaa B Sargi; Ricardo Komotar Journal: World Neurosurg Date: 2018-10-05 Impact factor: 2.104